Read by QxMD icon Read

Diabetes Technology & Therapeutics

Mercedes Rigla, Belén Pons, Pere Rebasa, Alexis Luna, Francisco Javier Pozo, Assumpta Caixàs, Maria Villaplana, David Subías, Maria Rosa Bella, Neus Combalia
BACKGROUND: Subcutaneous (s.c.) glucose sensors have become a key component in type 1 diabetes management. However, their usability is limited by the impact of foreign body response (FBR) on their duration, reliability, and accuracy. Our study gives the first description of human acute and subacute s.c. response to glucose sensors, showing the changes observed in the sensor surface, the inflammatory cells involved in the FBR and their relationship with sensor performance. METHODS: Twelve obese patients (seven type 2 diabetes) underwent two abdominal biopsies comprising the surrounding area where they had worn two glucose sensors: the first one inserted 7 days before and the second one 24 h before biopsy procedure...
February 22, 2018: Diabetes Technology & Therapeutics
Eleanor M Scott, Rudy W Bilous, Alexandra Kautzky-Willer
BACKGROUND: Accuracy of the FreeStyle Libre™ Flash Glucose Monitoring System has not been evaluated in pregnant women with diabetes. The aim of this study was to determine accuracy (compared to self-monitoring of blood glucose [SMBG]), clinical safety, and acceptability of the FreeStyle Libre System when used at home by this population. MATERIALS AND METHODS: Seventy-four participants, with type 1 (T1D, n = 24), type 2 (T2D, n = 11), or gestational (n = 39) diabetes, were enrolled across 13 sites (9 in United Kingdom, 4 in Austria)...
February 22, 2018: Diabetes Technology & Therapeutics
Garry M Steil
No abstract text is available yet for this article.
February 15, 2018: Diabetes Technology & Therapeutics
Sari Hoshina, Gregers S Andersen, Marit E Jørgensen, Martin Ridderstråle, Dorte Vistisen, Henrik U Andersen
BACKGROUND AND AIMS: The aim of this study was to evaluate the incidence rates of diabetic ketoacidosis (DKA) according to treatment modality in patients with type 1 diabetes (T1D) in Denmark, either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). MATERIALS AND METHODS: A total of 20,902 T1D registered in the Danish Adult Diabetes Database were followed for an average of 5.4 years. Poisson regression analyses with risk time as offset were used to compare differences in rates of DKA between CSII and MDI...
February 13, 2018: Diabetes Technology & Therapeutics
Bruce A Buckingham, Gregory P Forlenza, Jordan E Pinsker, Mark P Christiansen, R Paul Wadwa, Jennifer Schneider, Thomas A Peyser, Eyal Dassau, Joon Bok Lee, Jason O'Connor, Jennifer E Layne, Trang T Ly
BACKGROUND: The safety and feasibility of the OmniPod personalized model predictive control (MPC) algorithm in adult, adolescent, and pediatric patients with type 1 diabetes were investigated. METHODS: This multicenter, observational trial included a 1-week outpatient sensor-augmented pump open-loop phase and a 36-h inpatient hybrid closed-loop (HCL) phase with announced meals ranging from 30 to 90 g of carbohydrates and limited physical activity. Patients aged 6-65 years with HbA1c between 6...
February 12, 2018: Diabetes Technology & Therapeutics
Sediqeh Samadi, Mudassir Rashid, Kamuran Turksoy, Jianyuan Feng, Iman Hajizadeh, Nicole Hobbs, Caterina Lazaro, Mert Sevil, Elizabeth Littlejohn, Ali Cinar
BACKGROUND: Automatically attenuating the postprandial rise in the blood glucose concentration without manual meal announcement is a significant challenge for artificial pancreas (AP) systems. In this study, a meal module is proposed to detect the consumption of a meal and to estimate the amount of carbohydrate (CHO) intake. METHODS: The meals are detected based on qualitative variables describing variation of continuous glucose monitoring (CGM) readings. The CHO content of the meals/snacks is estimated by a fuzzy system using CGM and subcutaneous insulin delivery data...
February 6, 2018: Diabetes Technology & Therapeutics
Alexander Abitbol, Remi Rabasa-Lhoret, Virginie Messier, Laurent Legault, Mohamad Smaoui, Nathan Cohen, Ahmad Haidar
BACKGROUND: The dual-hormone (insulin and glucagon) artificial pancreas may be justifiable in some, but not all, patients. We sought to compare dual- and single-hormone artificial pancreas systems in patients with hypoglycemia unawareness and documented nocturnal hypoglycemia. METHODS: We conducted a randomized crossover trial comparing the efficacy of dual- and single-hormone artificial pancreas systems in controlling plasma glucose levels over the course of one night's sleep...
February 2, 2018: Diabetes Technology & Therapeutics
Mark P Christiansen, Leslie J Klaff, Ron Brazg, Anna R Chang, Carol J Levy, David Lam, Douglas S Denham, George Atiee, Bruce W Bode, Steven J Walters, Lynne Kelley, Timothy S Bailey
BACKGROUND: Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D). METHODS: PRECISE II was a nonrandomized, blinded, prospective, single-arm, multicenter study that evaluated the accuracy and safety of the implantable Eversense CGM system among adult participants with T1D and T2D (NCT02647905). The primary endpoint was the mean absolute relative difference (MARD) between paired Eversense and Yellow Springs Instrument (YSI) reference measurements through 90 days postinsertion for reference glucose values from 40 to 400 mg/dL...
January 30, 2018: Diabetes Technology & Therapeutics
Maria Ida Maiorino, Giuseppe Bellastella, Ofelia Casciano, Paolo Cirillo, Vittorio Simeon, Paolo Chiodini, Michela Petrizzo, Maurizio Gicchino, Ornella Romano, Paola Caruso, Dario Giugliano, Katherine Esposito
BACKGROUND: Type 1 diabetic patients have high instability of daily glucose levels. The aim of this study was to evaluate the long-term effects of continuous subcutaneous insulin infusion (CSII) therapy, compared with multiple daily injections of insulin (MDI), on glucose variability, in young type 1 diabetic patients transitioned to the adult diabetes care. METHODS: Patients aged 18-30 years and considered eligible for insulin pump therapy were included in the study...
January 5, 2018: Diabetes Technology & Therapeutics
Fumi Uemura, Yosuke Okada, Keiichi Torimoto, Yoshiya Tanaka
BACKGROUND: To determine the factors associated with hypoglycemia in patients with type 2 diabetes mellitus (T2DM) on insulin therapy. METHODS: This retrospective study included 62 inpatients with T2DM on insulin therapy who underwent 5-day continuous glucose monitoring (CGM). We analyzed the relation between hypoglycemia (defined as blood glucose below 70 mg/dL, as determined by the CGM) and time spent in hypoglycemia with fasting blood glucose, mean blood glucose (MBG), standard deviation (SD), coefficient of variation, minimum blood glucose level, maximum blood glucose level, and the percent time spent with blood glucose levels of >180 mg/dL...
January 2, 2018: Diabetes Technology & Therapeutics
Andrzej Gawrecki, Dorota Zozulinska-Ziolkiewicz, Bartlomiej Matejko, Jerzy Hohendorff, Maciej T Malecki, Tomasz Klupa
In this brief report, we describe the feat of four men with type 1 diabetes mellitus (T1DM) who decided to take part in a mountain ultramarathon in Bieszczady, Poland on May 27, 2016. Before participating in the competition, they asked two diabetologists for a consultation and to assist in diabetic control during the marathon. The aim of the study was to assess the metabolic safety in people with T1DM during extreme physical exertion in a mountain ultramarathon. All subjects were treated with continuous subcutaneous insulin infusion...
January 2, 2018: Diabetes Technology & Therapeutics
Giada Acciaroli, Martina Vettoretti, Andrea Facchinetti, Giovanni Sparacino
BACKGROUND: Continuous glucose monitoring (CGM) sensors need to be calibrated twice/day by using self-monitoring of blood glucose (SMBG) samples. Recently, to reduce the calibration frequency, we developed an online calibration algorithm based on a multiple-day model of sensor time variability and Bayesian parameter estimation. When applied to Dexcom G4 Platinum (DG4P) sensor data, the algorithm allowed the frequency of calibrations to be reduced to one-every-four-days without significant worsening of sensor accuracy...
December 21, 2017: Diabetes Technology & Therapeutics
Jennifer M Yamamoto, Helen R Murphy
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Aoibhe M Pasieka, Michael C Riddell
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Neal Kaufman, Maryam Dadashi
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Bimota Nambam, Natasa Bratina, Desmond Schatz
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Revital Nimri, Pearl Audon, Jordan E Pinsker, Eyal Dassau
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Thomas Danne, Lutz Heinemann, Jan Bolinder
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Tadej Battelino, Bruce W Bode
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
John C Pickup
No abstract text is available yet for this article.
February 2018: Diabetes Technology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"